EurekaMag.com logo
+ Translate

Electrophysiologic effects of intravenous and oral sotalol for sustained ventricular tachycardia secondary to coronary artery disease


, : Electrophysiologic effects of intravenous and oral sotalol for sustained ventricular tachycardia secondary to coronary artery disease. American Journal of Cardiology 61(13): 1006-1011

The electrophysiologic effects of intravenous sotalol (1.5 mg/kg load followed by 0.008 mg/kg maintenance, mean dose 150 .+-. 23 mg) and oral sotalol (mean dose 583 .+-. 204 mg daily) were prospectively evaluated in 16 patients undergoing electrophysiologic evaluation for sustained ventricular tachycardia (VT) secondary to coronary artery disease. Electrocardiographic intervals, indexes of sinus and atrioventricular node function and indexes of atrial and ventricular function were assessed. Inducibility or noninducibility of sustained VT and characteristics of the induced arrhythmia were also evaluated. Intravenous and oral sotalol exerted similar .beta.-blocking effects, which included significant prolongation of sinus cycle length (baseline 820 .+-. 165 ms, intravenous sotalol 1,077 .+-. 206 ms, oral sotalol 1,141 .+-. 306 ms), AH interval (baseline 126 .+-. 43, intravenous sotalol 169 .+-. 42, oral sotalol 197 .+-. 55 ms) and Wenckebach cycle length (baseline 375 .+-. 70, intravenous sotalol 460 .+-. 84, oral sotalol 449 .+-. 68 ms). Both intravenous and oral sotalol also prolonged repolarization and refractoriness including significant increases in QT interval (baseline 338 .+-. 47, intravenous sotalol 417 .+-. 35, oral sotalol 450 .+-. 70 ms), atrial effective refractory period (baseline 240 .+-. 38, intravenous sotalol 330 .+-. 71, oral sotalol 299 .+-. 26 ms) and right ventricular effective refractory period (baseline 241 .+-. 16, intravenous sotalol 289 .+-. 35, oral sotalol 291 .+-. 22 ms). Both intravenous and oral sotalol significantly slowed the cycle length of induced VT (baseline 265 .+-. 53, intravenous sotalol 351 .+-. 31, oral sotalol 331 .+-. 64 ms) and increased the mean arterial pressure during VT (baseline 45 .+-. 14 mm Hg, intravenous sotalol 78 .+-. 13 mm Hg, oral sotalol 65 .+-. 25 mm Hg). Intravenous and oral sotalol prevented induction of sustained VT in a similar percentage of patients (intravenous sotalol 2 of 9, 22%, oral sotalol 2 of 11, 18%). The observed electropharmacologic effects of intravenous and oral sotalol did not correlate with plasma concentration. Intravenous and oral sotalol have similar qualitative electrophysiologic effects but the specific quantitative effects observed may vary among individual patients.

Accession: 005349303

PMID: 3284316

DOI: 10.1016/0002-9149(88)90116-6

Download PDF Full Text: Electrophysiologic effects of intravenous and oral sotalol for sustained ventricular tachycardia secondary to coronary artery disease


Submit PDF Full Text

No spam - Every submission is manually reviewed

Due to poor quality, we do not accept files from Researchgate

Submitted PDF Full Texts will always be free for everyone
(We only charge for PDFs that we need to acquire)

Select a PDF file:
Close
Close

Related references

Kus T.; Campa M.A.; Nadeau R.; Dubuc M.; Kaltenbrunner W.; Shenasa M., 1992: Efficacy and electrophysiologic effects of oral sotalol in patients with sustained ventricular tachycardia caused by coronary artery disease. The efficacy of oral sotalol in preventing sustained ventricular tachycardia induction by invasive electrophysiological testing was assessed in 22 patients (60 .+-. 9 years) with prior myocardial infarction. Programmed stimulation consisted of two...

Easley A.R.; Mann D.E.; Reiter M.J.; Sakun V.; Sullivan S.M.; Magro S.A.; Luck J.C.; Wyndham C.R.C., 1986: Electrophysiologic evaluation of pirmenol for sustained ventricular tachycardia secondary to coronary artery disease. The efficacy and electrophysiologic effects of pirmenol were evaluated in 21 patients with a history of sustained ventricular tachycardia(VT) and coronary artery disease. Intravenous pirmenol (0.7-to 1.1-mg/kg bolus, followed by a 35- to 40-.mu.g/...

Pires, L.A.; Wagshal, A.B.; Greene, T.O.; Mittleman, R.S.; Huang, S.K.S.ephen, 1993: Usefulness of the response to intravenous procainamide during electrophysiologic study in predicting the response to oral quinidine in patients with inducible sustained monomorphic ventricular tachycardia associated with coronary artery disease. The response to intravenous procainamide (15 to 20 mg/kg) and to oral quinidine 324 to 648 mg every 8 hour for 3 to 5 days was prospectively studied in 50 consecutive patients (43 men and 7 women, aged 38 to 83 years old (mean 64 +- 11)) with coro...

Wynn, J.; Miura, D.S.; Torres, V.; Flowers, D.; Keefe, D.; Williams, S.; Somberg, J.C., 1985: Electrophysiologic evaluation of the antiarrhythmic effects of N-acetylprocainamide for ventricular tachycardia secondary to coronary artery disease. Antiarrhythmic properties of N-acetylprocainamide (NAPA), an active metabolite of procainamide, were studied in 12 patients with coronary artery disease who presented with cardiac arrest or documented sustained ventricular tachycardia (VT). Progra...

Hoffmann, E.; Mattke, S.; Haberl, R.; Steinbeck, G., 1993: Randomized crossover comparison of the electrophysiologic and antiarrhythmic efficacy of oral cibenzoline and sotalol for sustained ventricular tachycardia. We compared the electrophysiologic and clinical effects of oral cibenzoline and sotalol in 12 patients with spontaneous and inducible sustained ventricular tachycardia (VT), using a randomized, open-label, cross-over study. Electrophysiologic stud...

Boecker, D.; Haverkamp, W.; Block, M.; Borggrefe, M.; Breithadt, G., 1996: Implantable defibrillators are superior to d,l-Sotalol for treatment of sustained ventricular tachycardia or fibrillation in patients with coronary artery disease. Journal of the American College of Cardiology 27(2 SUPPL A): 402A

Böcker, D.; Haverkamp, W.; Block, M.; Borggrefe, M.; Hammel, D.; Breithardt, G., 1996: Comparison of d,l-sotalol and implantable defibrillators for treatment of sustained ventricular tachycardia or fibrillation in patients with coronary artery disease. Background: Implantable cardioverter-defibrillators (ICDs) and d,l-sotalol are widely used to treat ventricular tachyarrhythmia and ventricular fibrillation (VT/VF). The purpose of this study was to compare the long-term efficacy of d,l-sotalol an...

Man, K.C.ing; Williamson, B.D.; Niebauer, M.; Daoud, E.; Bakr, O.; Strickberger, S.A.am; Hummel, J.D.; Kou, W.; Morady, F., 1994: Electrophysiologic effects of Sotalol and amiodarone in patients with sustained monomorphic ventricular tachycardia. No prospective studies have compared sotalol and amiodarone during electropharmacologic testing. The purpose of this prospective, randomized study was to compare the electrophysiologic effects of sotalol and amiodarone in patients with coronary ar...

Man, K.C.; Williamson, B.D.; Niebauer, M.; Daoud, E.; Bakr, O.; Strickberger, S.A.; Hummel, J.D.; Kou, W.; Morady, F., 1994: Electrophysiologic effects of sotalol and amiodarone in patients with sustained monomorphic ventricular tachycardia. No prospective studies have compared sotalol and amiodarone during electropharmacologic testing. The purpose of this prospective, randomized study was to compare the electrophysiologic effects of sotalol and amiodarone in patients with coronary ar...

Boriani, G.; Biffi, M.; Bacchi, L.; Martignani, C.; Zannoli, R.; Butrous, G.S.; Branzi, A., 2002: A randomised cross-over study on the haemodynamic effects of oral dofetilide compared with oral sotalol in patients with ischaemic heart disease and sustained ventricular tachycardia. Objective: To assess the haemodynamic effects of short-term treatment with dofetilide in comparison with sotalol in patients with ischaemic heart disease. Methods: Twelve patients with ischaemic heart disease and sustained ventricular tachycardia...